Identifying individuals with mutations in breast/ovarian cancer susceptibility genes is clinically important as BRCA1/2 carriers have been shown to have increased sensitivity to the novel poly-ADP-ribose (PARP) inhibitors [41], [42]. This evidence concerns the gene BRCA1 and ovarian carcinoma.